PHASE IB STUDY OF PF-04449913, A HEDGEHOG (HH) INHIBITOR, IN COMBINATION WITH LOW-DOSE CYTARABINE OR INTENSIVE CHEMOTHERAPY, IN ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)

被引：0
|
作者：
Cortes, J. [1 ]
O'Connell, A. [2 ]
Shaik, M. N. [3 ]
Cesari, R. [4 ]
Abbattista, A. [4 ]
Woolfson, A. [5 ]
Pollyea, D. [6 ]
Savona, M. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Pfizer Oncol, Collegeville, PA USA
[3] Pfizer Oncol, La Jolla, CA USA
[4] Pfizer Oncol, Milan, Italy
[5] Pfizer Oncol, New York, NY USA
[6] Univ Colorado, Ctr Canc, Aurora, CO USA
[7] Tennessee Oncol, Nashville, TN USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P179
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [1] A PHASE 2 STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
    Cortes, J. E.
    Smith, B. D.
    Wang, E. S.
    Merchant, A.
    Oehler, V. G.
    Arellano, M.
    DeAngelo, D. J.
    Pollyea, D. A.
    Ma, W. W.
    Zeremski, M.
    Shaik, M. N.
    O'Connell, A.
    Chan, G.
    Schroeder, M. A.
    HAEMATOLOGICA, 2017, 102 : 50 - 50
  • [2] A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    Cortes, Jorge E.
    Heidel, Florian H.
    Heuser, Michael
    Fiedler, Walter
    Smith, B. Douglas
    Robak, Tadeusz
    Fernandez, Pau Montesinos
    Ma, Weidong Wendy
    Shaik, M. Naveed
    Zeremski, Mirjana
    O'Connell, Ashleigh
    Chan, Geoffrey
    BLOOD, 2016, 128 (22)
  • [3] Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
    Savona, Michael R.
    Pollyea, Daniel A.
    Stock, Wendy
    Oehler, Vivian G.
    Schroeder, Mark A.
    Lancet, Jeffrey
    McCloskey, James
    Kantarjian, Hagop M.
    Ma, Weidong Wendy
    Shaik, Naveed
    Laird, A. Douglas
    Zeremski, Mirjana
    O'Connell, Ashleigh
    Chan, Geoffrey
    Cortes, Jorge E.
    CLINICAL CANCER RESEARCH, 2018, 24 (10) : 2294 - 2303
  • [4] Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome
    Márcio Tavares
    Sérgio Chacim
    José Mário Mariz
    Annals of Hematology, 2021, 100 : 837 - 839
  • [5] Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome
    Tavares, Marcio
    Chacim, Sergio
    Mariz, Jose Mario
    ANNALS OF HEMATOLOGY, 2021, 100 (03) : 837 - 839
  • [6] Phase I evaluation of tipifarnib in combination with low-dose Ara-C (LDAC) in high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Interim results
    Cortes, J. E.
    Feldman, E. J.
    Douer, D.
    Raza, A.
    Fruchtman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] PHASE 1B STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME, OLIGOBLASTIC ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA
    Borate, U.
    Smith, B. D.
    Gore, S.
    Zeidan, A.
    Savona, M.
    Savoie, M. L.
    Zhu, N.
    Breems, D.
    Zhang, X.
    Shaik, M. N.
    Rampersad, A.
    Chan, G.
    Woolfson, A.
    Sekeres, M.
    HAEMATOLOGICA, 2016, 101 : 73 - 74
  • [8] Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
    Yamauchi, Takahiro
    Negoro, Eiju
    Arai, Hajime
    Ikegaya, Satoshi
    Takagi, Kazutaka
    Takemura, Haruyuki
    Inai, Kunihiro
    Yoshida, Akira
    Urasaki, Yoshimasa
    Iwasaki, Hiromichi
    Ueda, Takanori
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2635 - 2639
  • [9] Tipifarnib in combination with idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
    Ravandi-Kashani, F.
    Kantarjian, H.
    Garcia-Manero, G.
    O'Brien, S.
    Verstovsek, S.
    Estrov, Z.
    Faderl, S.
    Giles, F.
    Wright, J.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 351S - 351S
  • [10] A Phase 2 Study of the Hedgehog Pathway Smoothened Inhibitor PF-04449913 to Reduce Relapse in High Risk Acute Leukemia and MDS Patients Following Allogeneic Stem Cell Transplantation
    Gutman, Jonathan A.
    Denoncourt, Emily
    Schatz, Derek
    Smith, Clayton
    Pollyea, Daniel Aaron
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S286 - S286
12345